Enquiries to Ministry of Health 0800 855 066

## APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 1 Form SA2306 May 2024

| APPLICANT (stamp or sticker acceptable)  |   |        |        |   | PATIENT NHI:   | REFERRER Reg No:                             |  |  |
|--|---|--------|--------|---|--|--|--|--|
| Reg No:  |   |        |        |   | First Names:   | First Names:                                 |  |  |
| Name:  |   |        |        |   | Surname:   | Surname:                                     |  |  |
| Address:   |   |        |        |   | DOB:   | Address:                                     |  |  |
|  |   |        |        |   | Address:   |  |  |  |
|  |   |        |        |   |  |  |  |  |
| Fax N  | umbe  | r:     |        |   |  | Fax Number:                                  |  |  |
| Nivo   | luma  | ıb     |        |   |  |  |  |  |
| Appli  |   | is onl | y fron | n a medical oncologist. Approxes where appropriate) | ovals valid for 4 months.  |  |  |  |
|  | ].  |        | Patie  | nt has metastatic or unresect                       | able melanoma (excluding uveal) stage III or IV  |  |  |  |
|  | and<br>[  |        | Basel  | ine measurement of overall t                        | umour burden is documented clinically and radiologic   | eally  |  |  |
|  | and   |        | The c  | eatient has ECOG performan                          | ce score of 0-2  |  |  |  |
|  | and   | _      |        |   |  |  |  |  |
|  | Patient has not received funded pembrolizumab  or |        |        |   |  |  |  |  |
|  |   |        |        | 12 weeks of starting to                             | is received an initial Special Authority approval for pembrolizumab and has discontinued pembrolizumab within of starting treatment due to intolerance |  |  |  |
|  |   |        | an     |   | ogress while the patient was on pembrolizumab  |  |  |  |
| and  Documentation confirming that the patient has been informed and acknowledges that funded treatment with n continued if their disease progresses |   |        |        |   |  | unded treatment with nivolumab will not be   |  |  |
| Renewal — less than 24 months on treatment  Current approval Number (if known):  |   |        |        |   |  |  |  |  |
|  |   |        | or     | Patient's disease has                               | had a complete response to treatment   |  |  |  |
|  |   |        |        | Patient's disease has                               | had a partial response to treatment  |  |  |  |
|  |   |        | or     | Patient has stable disc                             | ease   |  |  |  |
|  |   | and    |        | Response to treatment in tartreatment period        | rget lesions has been determined by comparable radi  | iologic assessment following the most recent |  |  |
|  |   |        |        | The treatment remains clinic                        | ally appropriate and the patient is benefitting from the   | e treatment                                  |  |  |
|  | or  | and    |        | Patient has previously disco                        | ntinued treatment with nivolumab for reasons other th  | nan severe toxicity or disease progression   |  |  |
|  |   | and    |        | Patient has signs of disease                        | progression  |  |  |  |
|  |   |        |        | Disease has not progressed                          | during previous treatment with nivolumab   |  |  |  |
|  |   |        |        |   |  |  |  |  |

I confirm the above details are correct and that in signing this form I understand I may be audited.

Enquiries to Ministry of Health 0800 855 066

## APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 2 Form SA2306 May 2024

| APPLICANT (stamp or sticker acceptable)  | PATIENT NHI:  | REFERRER Reg No:  |
|--|---|---|
| Reg No:  | First Names:  | First Names:  |
| Name:  | Surname:  | Surname:  |
| Address:   | DOB:  | Address:  |
|  | Address:  |   |
|  |   |   |
| Fax Number:  |   | Fax Number:   |
| Nivolumab - continued  |   |   |
| Prerequisites (tick boxes where appropriate)  Patient has been on treatment for and  Patient's diseas or Patient's diseas or Patient has state and Response to treatment the most recent treatment the most recent treatment remains or Patient has previously and Patient has signs of displayed and Pa | dical practitioner on the recommendation of a medical more than 24 months  e has had a complete response to treatment e has had a partial response to treatment ble disease  It in target lesions has been determined by comparable nent period s clinically appropriate and the patient is benefitting from the discontinued treatment with nivolumab for reasons of | le radiologic or clinical assessment following om the treatment |